Crescent Biopharma, Inc.
CBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,605,484 | $14,948,822 | $15,916,945 | $7,409,261 |
| - Cash | $34,766 | $41,793 | $47,871 | $90,255 |
| + Debt | $37,482 | $808 | $919 | $1,920 |
| Enterprise Value | $1,608,200 | $14,907,837 | $15,869,993 | $7,320,927 |
| Revenue | $0 | $10 | $75 | $1,160 |
| % Growth | -100% | -86.7% | -93.5% | – |
| Gross Profit | $0 | $10 | $75 | $1,160 |
| % Margin | – | 100% | 100% | 100% |
| EBITDA | $0 | -$39,121 | -$47,196 | -$63,183 |
| % Margin | – | -391,213.6% | -62,927.6% | -5,447.9% |
| Net Income | -$71,468 | -$36,899 | -$46,689 | -$63,427 |
| % Margin | – | -368,994.2% | -62,251.7% | -5,469% |
| EPS Diluted | -0.59 | -0.58 | -0.89 | -1.23 |
| % Growth | -1.7% | 34.8% | 27.6% | – |
| Operating Cash Flow | -$31,098 | -$34,880 | -$46,457 | -$57,490 |
| Capital Expenditures | -$10 | -$21 | -$84 | -$15 |
| Free Cash Flow | -$31,108 | -$34,901 | -$46,542 | -$57,504 |